MapLight Therapeutics, Inc. MPLT

Set alert

Price alert · MPLT

All alert types
6.78 USD -0.80 -10.55%

At close

6.78 0.00 0.00%

Pre-market · Nov 3, 4:19 AM ET

Bid
6.77 × 1
Ask
6.79 × 2
6.77 Day range 7.67
6.77 52-week range 40.43
YTD
-61.41%
1 year
-59.93%
Open
7.65
Prev close
7.58
Mkt cap
376.80M
Vol
245.51K
Avg vol
509.15K
EPS
-6.25
P/E
0.00
Div yield
0.00%
More statistics
Low
6.77
High
7.67
Forward P/E
-10.51
Beta
0.00
Short ratio
5.58
Inst. own
56.01%
Dividend
0.00
Ex-div date
Earnings
Sep 18, 2026
50-d avg
30.61
200-d avg
22.20
1y target
41.50

5D chart

Chart tools
Interval

Chart is warming up

The five-day price history for MPLT has not been loaded yet. Try again in a moment.

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 41.50 +512.1% upside
Target (low)
30.00
Target (mean)
41.50
Target (high)
60.00
Ratings (0m) 13 13 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy11
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 13
  • 1 month ago 12
  • 2 months ago 11
  • 3 months ago 7

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

MPLT analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-1.40-1.45 – -1.320.000.0%00.0%7
Next quarter-1.26-1.35 – -1.060.000.0%00.0%7
Current year-5.14-5.41 – -4.65-18.56+72.3%00.0%7
Next year-3.74-5.30 – -0.10-5.14+27.3%20.00M0.0%7

Upgrades and downgrades

The latest rating changes

MPLT analyst upgrades and downgrades
DateFirmActionFromTo
Jul 10, 2026NeedhamMaintainedBuyBuy
Jun 25, 2026Raymond JamesInitiated—Strong Buy
Jun 23, 2026Craig-HallumMaintainedBuyBuy
Jun 22, 2026NeedhamMaintainedBuyBuy
Jun 2, 2026StifelMaintainedBuyBuy
May 28, 2026HC Wainwright & Co.ReiteratedBuyBuy
May 27, 2026UBSInitiated—Buy
May 21, 2026Craig-HallumInitiated—Buy
May 4, 2026HC Wainwright & Co.Initiated—Buy
Apr 8, 2026NeedhamInitiated—Buy
Apr 7, 2026TD CowenInitiated—Buy
Mar 19, 2026Canaccord GenuityInitiated—Buy
Nov 21, 2025JefferiesInitiated—Buy
Nov 21, 2025Leerink PartnersInitiated—Outperform
Nov 21, 2025StifelInitiated—Buy
Nov 21, 2025Morgan StanleyInitiated—Overweight